Aster Bio

Preclinical biotech

Engineering cellular resilience against age-related disease.

Small molecules that restore how aged cells respond to stress. Our lead program, AST-201, begins IND-enabling studies in 2027.

Explore the platform

Platform

Three steps from aging biology to a medicine.

We start from human aging data, not a single target. Every program moves through the same three stages, in this order.

  1. Cellular atlas

    We profile 2.4 million aged human cells across 14 tissues to find where stress responses fail first.

  2. Molecule design

    A structure-guided chemistry platform designs small molecules that restore those responses, and only those.

  3. Translational models

    Candidates are tested in human organoids and aged mouse cohorts before a single patient is dosed.

Publications

Peer-reviewed, and published in full.

Our datasets and methods go out with every paper, so other labs can check the work.

  • Peer-reviewed

    A small-molecule eIF2B activator restores stress recovery in aged human fibroblasts

    Aging Mechanisms · Okonkwo R, Lindqvist M, Rao P, et al.

    doi:10.5555/ast.2026.0806

  • Peer-reviewed

    A single-cell atlas of stress-response decline across 14 human tissues

    Cell Resilience Reports · Rao P, Adeyemi K, Moreau L, et al.

    doi:10.5555/ast.2026.0318

  • Preprint

    AST-201 preserves cardiac function in 24-month-old mice without weight loss

    Molecular Gerontology Letters · Lindqvist M, Hart E, Chen Y, et al.

    doi:10.5555/ast.2025.1120